The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

19 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: part 2. Pyridazine-based analogs.EBI
Janssen Research And Development
4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: urea-based analogs.EBI
Janssen Research And Development
Benzimidazole-carboxamides as potent and bioavailable stearoyl-CoA desaturase (SCD1) inhibitors from ligand-based virtual screening and chemical optimization.EBI
Sanofi-Aventis Deutschland
Discovery of liver-targeted inhibitors of stearoyl-CoA desaturase (SCD1).EBI
Merck Research Laboratories
Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.EBI
Merck Frosst Centre For Therapeutic Research
Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series.EBI
Merck Frosst Centre For Therapeutic Research
Nicotinic acids: liver-targeted SCD inhibitors with preclinical anti-diabetic efficacy.EBI
Merck Frosst Centre For Therapeutic Research
Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series.EBI
Merck Frosst Centre For Therapeutic Research
Conversion of systemically-distributed triazole-based stearoyl-CoA desaturase (SCD) uHTS hits into liver-targeted SCD inhibitors.EBI
Merck Frosst Centre For Therapeutic Research
Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: from systemic to liver-targeting inhibitors.EBI
Merck Frosst Centre For Therapeutic Research
N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors.EBI
Pfizer
2-Aryl benzimidazoles: human SCD1-specific stearoyl coenzyme-A desaturase inhibitors.EBI
Merck Frosst Centre For Therapeutic Research
SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors.EBI
Merck Frosst Centre For Therapeutic Research
Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).EBI
Merck Frosst Centre For Therapeutic Research
Thiazole analog as stearoyl-CoA desaturase 1 inhibitor.EBI
Merck Frosst Centre For Therapeutic Research
Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.EBI
Gilead Sciences
Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.EBI
Cv Therapeutics